Crohn's jejunoileitis: The pediatrician's perspective on diagnosis and management

Inflammatory Bowel Diseases

Volumn 11, Issue 7, 2005, Pages 696-704

  Cuffari, Carmen ^a,e   Dubinsky, Marla ^b   Darbari, Anil ^a   Sena, Laureen ^c   Baldassano, Robert ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cedar Sinai Medical Center   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Crohn's disease; Diagnosis and therapy; Jejunoileitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GADOLINIUM;

CARD15 GENE; CLINICAL FEATURE; CROHN DISEASE; CROHN JEJUNOILEITIS; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ENDOSCOPY; FISTULA; GENE; GENOTYPE; HUMAN; ILEITIS; INTESTINE OBSTRUCTION; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIODIAGNOSIS; REVIEW; RISK FACTOR; TREATMENT PLANNING;

ADOLESCENT; CHILD; CROHN DISEASE; DIAGNOSTIC IMAGING; ENDOSCOPY, GASTROINTESTINAL; ENTERITIS; HUMANS; ILEITIS; JEJUNAL DISEASES; PHENOTYPE;

EID: 21844452967     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000166933.74477.69     Document Type: Review

References (67)

1. Cuffari C, Darbari A. Inflammatory bowel disease in the pediatric and adolescent patient. Gastro Clin North Am. 2002;31:275-292.
2. Cuffari C, Bayless TM. Crohn's disease: age of onset determines clinical phenotype. Gastroenterol Int. 1997;10:89.
3. Seidman E. Inflammatory bowel diseases. In: Roy CC, Silverman A, Alagille D, eds. Pediatric Clinical Gastroenterology. 4th ed. St. Louis, MO: Mosby-Year Book; 1995:427.
4. Polito JM II, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-586.
5. Brant SR, Panhuysen CI, Bailey-Wilson JE, et al. Linkage heterogeneity for the IBDI locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000;119:1483-1490.
6. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology. 2003;124:521-536.
7. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
8. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
9. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122: 854-866.
10. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
11. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8-15.
12. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
13. Dubinsky MC, Lee-Uy N, Lin YC, et al. Synergism of NOD2 and ASCA contributes to disease behavior in pediatric Crohn's disease patients. Gastroenterology. 2003:A372.
14. Jamieson DH, Shipman PJ, Israel DM, et al. Comparison of multidetector CT and barium studies of the small bowel: inflammatory bowel disease in children. AJR Am J Roentgenol. 2003;180:1211-1216.
15. Horton KM, Fishman EK. The current status of multidetector row CT and three-dimensional imaging of the small bowel. Radial Clin North Am. 2003;41:199-212.
16. Charron M, del Rosario FJ, Kocoshis SA. Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology. 1999;212:507-513.
17. Charron M. Pediatric inflammatory bowel disease imaged with Tc-99m white blood cells. Clin Nucl Med. 2000;25:708-715.
18. Davison SM, Chapman S, Murphy MS. 99mTc-HMPAO leucocyte scintigraphy fails to detect Crohn's disease in the proximal gastrointestinal tract. Arch Dis Child. 2001;85:43-46.
19. Haber HP, Busch A, Ziebach R, et al. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med. 2002;21: 375-382.
20. Van Oostayen JA, Wasser MN, van Hogezand RA, et al. Activity of Crohn disease assessed by measurement of superior mesenteric artery flow with Doppler US. Radiology. 1994;193:551-554.
21. Potthast S, Rieber A, Von Tirpitz C, et al. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol. 2002; 12:1416-1422.
22. Darbari A, Sena L, Argani P, et al. Gadolinium enhanced magnetic resonance imaging: A useful radiologic tool in diagnosing pediatric IBD. Inflamm Bowel Dis. 2004;10:67-72.
23. Maccioni F, Viscido A, Broglia L, et al. Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging. 2000;25:219-228.
24. Low RN, Francis IR. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT. AJR Am J Roentgenol. 1997;169:1051-1059.
25. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988;94:603-610.
26. Benz C, Jakobs R, Riemann JF. Do we need the overtube for push-enteroscopy? Endoscopy. 2001;33:658-661.
27. Benz C, Jakobs R, Riemann JF. Does the insertion depth in push enteroscopy depend on the working length of the enteroscope? Endoscopy. 2002;34:543-545.
28. Linder J, Cheruvartath R, Truss C, et al. Diagnostic yield and clinical implications of push enteroscopy: results from a nonspecialized center. J Clin Gastroenterol. 2002;35:383-386.
29. Darbari A, Kaloo A, Cuffari C. Push enteroscopy and G-MRI are effective diagnostic tools for pediatric proximal small bowel Crohn's disease. Gastrointest Endosc. 2004;59:AB104.
30. American Society for Gastrointestinal Endoscopy Technology Assessment Committee. Wireless capsule endoscopy. Gastrointest Endosc. 2002; 56:621-624.
31. Iddan G, Meron G, Glukhovsky A, et al. Wireless capsule endoscopy. Nature. 2000;405:417.
32. Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut. 2003;52:390-392.
33. Appleyard M, Fireman Z, Glukhovsky A, et al. A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions. Gastroenterology. 2000;119:1431-1438.
34. Liangpunsakul S, Chadalawada V, Rex DK, et al. Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis. Am J Gastroenterol. 2003;98:1295-1298.
35. Wagtmans MJ, Verspaget HW, Lamers CB, et al. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol. 1997;92:1467-1471.
36. Attard TM, Horton S, DeVito S, et al. Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional support. Inflamm Bowel Dis. 2004;10:357-360.
37. Pritchard TJ, Schoetz DJ, Caushaj FP, et al. Stricturoplasty of the small bowel in patients with Crohn's disease. Arch Surg. 1990;125:715-717.
38. Kombluth A, Solomon P, Sachar DB. Crohn's disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Diseases. Philadelphia, PA: WB Saunders; 1993:1270-1304.
39. Walker-Smith JA. Management of growth failure in Crohn's disease. Arch Dis Child. 1996;75;351-354.
40. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:297-321.
41. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003;3:81-92.
42. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-1301.
43. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther. 2000;14:163-169.
44. Sandborn W, Hanauer S. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
45. Fallingborg J, Christensen LA, Jacobsen BA, et al. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci. 1993; 38:1989-1993.
46. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979; 77:847-869.
47. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
48. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2003;3: CD000543.
49. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
50. Lewis JD. How safe are the safest IBD drugs? Gastroenterology. 2003;124:1986-1987.
51. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
52. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr. 2002;140:75-80.
53. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
54. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 1999; 94:878-883.
55. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
56. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A longterm, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
57. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
58. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342:1627-1632.
59. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med. 1989;111:641-649.
60. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology. 1995;108:1056-1067.
61. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study IV. Gastroenterology. 1991; 101:881-888.
62. Papadopoulou A, Holden CE, Paul L, et al. The nutritional response to home enteral nutrition in childhood. Acta Paediatr. 1995;84:528-531.
63. Hyams JS, Moore RE, Leichtner AM, et al. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr. 1988;112:893-898.
64. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
65. Cuffari C, Lichtenstein GR. Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent? Gastroenterology. 2003;124:1988-1990.
66. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111.
67. Ozuner G, Fazio VW, Lavery IC, et al. Reoperative rates for Crohn's disease following stricturoplasty. Dis Colon Rectum. 1996;39:1199-1203.